DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/477bv2/cytokine_therapy) has announced the addition of the "Cytokine Therapy in Oncology Drug Pipeline Update 2013" report to their offering.
In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 7 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 20 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 19 out of the 19 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 6 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Includes more than 82 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
This Drug Pipeline Update contains 106 cytokine drugs in development, which have a total of 208 developmental projects in cancer. In addition there are suspended and ceased drugs.
Included cytokine drugs are also in development for 127 other indications, where of 52 are different cancer indications.
The identity of available biological structures on 14 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 72 structures available today among drug targets.
For more information visit http://www.researchandmarkets.com/research/477bv2/cytokine_therapy
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.